EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

bezafibrate
2-{4-[2-(4-chlorobenzamido)ethyl]phenoxy}-2-methylpropanoic acid

Supplier Sponsors

CAS Number: 41859-67-0Picture of molecule3D/inchi
ECHA EINECS - REACH Pre-Reg:255-567-9
FDA UNII: Y9449Q51XH
Nikkaji Web:J16.626J
Beilstein Number:4267656
MDL:MFCD00078970
XlogP3:3.80 (est)
Molecular Weight:361.82420000
Formula:C19 H20 Cl N O4
BioActivity Summary:listing
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:pharmaceuticals / chemical synthisis
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 
Physical Properties:
Assay: 95.00 to 100.00
Food Chemicals Codex Listed: No
Melting Point: 186.00 °C. @ 760.00 mm Hg
Boiling Point: 572.10 °C. @ 760.00 mm Hg (est)
Flash Point: 572.00 °F. TCC ( 299.80 °C. ) (est)
logP (o/w): 2.504 (est)
Soluble in:
 water, 1.224 mg/L @ 25 °C (est)
 
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
None found
 
Suppliers:
BOC Sciences
For experimental / research use only.
Bezafibrate >98%
Odor: characteristic
Use: Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used for the treatment of hyperlipidaemia. It helps to lower LDL cholesterol and triglyceride in the blood, and increase HDL.
George Uhe Company
Bezafibrate
Santa Cruz Biotechnology
For experimental / research use only.
Bezafibrate
Sigma-Aldrich: Sigma
For experimental / research use only.
Bezafibrate ≥98%, solid
sds
 
Safety Information:
Preferred SDS: View
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
oral-man TDLo 514 mg/kg/60D-
PERIPHERAL NERVE AND SENSATION: SENSORY CHANGE INVOLVING PERIPHERAL NERVE
British Medical Journal. Vol. 309, Pg. 929, 1994.

oral-man TDLo 1326 mg/kg/37W
KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"
Lancet. Vol. 341, Pg. 371, 1993.

intraperitoneal-mouse LD50 500 mg/kg
Medicamentos de Actualidad. Vol. 15, Pg. 215, 1979.

oral-mouse LD50 723 mg/kg
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
Kiso to Rinsho. Clinical Report. Vol. 22, Pg. 4293, 1988.

intraperitoneal-rat LD50 505 mg/kg
Medicamentos de Actualidad. Vol. 15, Pg. 215, 1979.

oral-rat LD50 1082 mg/kg
GASTROINTESTINAL: TUMORS BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
Kiso to Rinsho. Clinical Report. Vol. 22, Pg. 4293, 1988.

Dermal Toxicity:
subcutaneous-mouse LD50 1635 mg/kg
Drugs in Japan Vol. -, Pg. 1226, 1995.

subcutaneous-rat LD50 1580 mg/kg
GASTROINTESTINAL: TUMORS LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Kiso to Rinsho. Clinical Report. Vol. 22, Pg. 4293, 1988.

Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
pharmaceuticals / chemical synthisis
Recommendation for bezafibrate usage levels up to:
 not for fragrance use.
 
Recommendation for bezafibrate flavor usage levels up to:
 not for flavor use.
 
Safety References:
EPI System: View
ClinicalTrials.gov:search
Daily Med:search
Chemical Carcinogenesis Research Information System:Search
AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :39042
National Institute of Allergy and Infectious Diseases:Data
WGK Germany:1
2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
Chemidplus:0041859670
RTECS:UE8755000 for cas# 41859-67-0
 
References:
 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
NIST Chemistry WebBook:Search Inchi
Pubchem (cid):39042
Pubchem (sid):135001112
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
CHEBI:View
CHEMBL:View
KEGG (GenomeNet):D01366
HMDB (The Human Metabolome Database):Search
MedlinePlusSupp:View
ChemSpider:View
Wikipedia:View
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 not found in nature
 
Synonyms:
 azufibrat
 befibrat
 bezafibratum
 bezalande
 bezapuren
2-(p-(2-(p-chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid
2-[4-[2-(4-chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid
2-[p-[2-(p-chlorobenzamido)ethyl]phenoxy]-2-methylpropionic acid
2-[p-[2-p-chlorobenzamido)ethyl]phenoxy]-2-methylpropionic acid
2-{4-[2-(4-chlorobenzamido)ethyl]phenoxy}-2-methylpropanoic acid
2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-propanoic acid
2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
2-(4-{2-[(4-chlorophenyl)carbonylamino]ethyl}phenoxy)-2-methylpropanoic acid
 difaterol
 durabezur
 propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-
 propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-
 propionic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-
 reducterol
 sklerofibrat
 

Articles:

PubMed:Irrigation of root vegetables with treated wastewater: evaluating uptake of pharmaceuticals and the associated human health risks.
PubMed:Quantitative evaluation of initial symptoms as predictors to detect adverse drug reactions using Bayes' theory: expansion and evaluation of drug-adverse drug reaction-initial symptom combinations using adverse event reporting system database.
PubMed:Biodegradability of pharmaceutical compounds in agricultural soils irrigated with treated wastewater.
PubMed:Long-chain free fatty acid profiling analysis by liquid chromatography-mass spectrometry in mouse treated with peroxisome proliferator-activated receptor α agonist.
PubMed:Melanocortin 4 receptor becomes an ACTH receptor by coexpression of melanocortin receptor accessory protein 2.
PubMed:Dill seed extract improves abnormalities in lipid metabolism through peroxisome proliferator-activated receptor-α (PPAR-α) activation in diabetic obese mice.
PubMed:Structural Features and Transcriptional Activity of Chicken PPARs (α, β, and γ).
PubMed:Peroxisome proliferator-activated receptor α (PPARα) activation advances locomotor activity and feeding daily rhythms in mice.
PubMed:Bezafibrate, a lipid-lowering pharmaceutical, as a potential endocrine disruptor in male zebrafish (Danio rerio).
PubMed:Activation of peroxisome proliferator-activated receptor-α (PPARα) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes.
PubMed:Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up.
PubMed:Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
PubMed:Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes.
PubMed:Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling.
PubMed:Ecotoxicity assessment of lipid regulators in water and biologically treated wastewater using three aquatic organisms.
PubMed:Bezafibrate, a peroxisome proliferator-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice.
PubMed:Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.
PubMed:Differential effects of pyrazinamide and clofibrate on gene expression of rat hepatic alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, a key enzyme of the tryptophan-NAD pathway.
PubMed:Ethanolamine modulates DNA synthesis through epidermal growth factor receptor in rat primary hepatocytes.
PubMed:Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites.
PubMed:Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats.
PubMed:Hypertriglyceridemia: associated risks and effect of drug treatment.
PubMed:Bezafibrate-induced anaphylactic shock: unusual clinical presentation.
PubMed:Bezafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue.
PubMed:Beneficial changes in serum apo A-1 and its ratio to apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait.
PubMed:Activators of peroxisome proliferator-activated receptor-alpha induce the expression of the uncoupling protein-3 gene in skeletal muscle: a potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth.
PubMed:The patient at risk: who should we be treating?
PubMed:The patient at risk: who should we be treating?
PubMed:Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
PubMed:Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates.
PubMed:The role of NADPH in the regulation of glucose-6-phosphate and 6-phosphogluconate dehydrogenases in rat adipose tissue.
PubMed:Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
PubMed:Modification of low density lipoproteins from hypertriglyceridemic patients by macrophages in vitro and the effect of bezafibrate treatment.
 
Notes:
an antilipemic agent that lowers cholesterol and triglycerides. it decreases low density lipoproteins and increases high density lipoproteins.
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy